These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. Tambaro FP; De Novellis D; Wierda WG J Exp Pharmacol; 2021; 13():923-935. PubMed ID: 34744463 [TBL] [Abstract][Full Text] [Related]
8. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Zhang D; Harris HM; Chen J; Judy J; James G; Kelly A; McIntosh J; Tenn-McClellan A; Ambing E; Tan YS; Lu H; Gajewski S; Clifton MC; Yung S; Robbins DW; Pirooznia M; Skånland SS; Gaglione E; Mhibik M; Underbayev C; Ahn IE; Sun C; Herman SEM; Noviski M; Wiestner A Blood; 2023 Mar; 141(13):1584-1596. PubMed ID: 36375120 [TBL] [Abstract][Full Text] [Related]
10. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Kil LP; de Bruijn MJ; van Hulst JA; Langerak AW; Yuvaraj S; Hendriks RW Am J Blood Res; 2013; 3(1):71-83. PubMed ID: 23359016 [TBL] [Abstract][Full Text] [Related]
11. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
13. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance. St-Pierre F; Ma S Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566 [TBL] [Abstract][Full Text] [Related]
14. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078 [TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases. Huang J; Ma Z; Peng X; Yang Z; Wu Y; Zhong G; Ouyang T; Chen Z; Liu Y; Wang Q; Chen J; Chen T; Zeng Z J Med Chem; 2024 Feb; 67(4):2438-2465. PubMed ID: 38321747 [TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy. Li YQ; Lannigan WG; Davoodi S; Daryaee F; Corrionero A; Alfonso P; Rodriguez-Santamaria JA; Wang N; Haley JD; Tonge PJ J Med Chem; 2023 Jun; 66(11):7454-7474. PubMed ID: 37195170 [TBL] [Abstract][Full Text] [Related]
17. Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL. Aslan B; Kismali G; Chen LS; Iles LR; Mahendra M; Peoples M; Gagea M; Fowlkes NW; Zheng X; Wang J; Vellano CP; Marszalek JR; Bertilaccio MTS; Gandhi V Blood Adv; 2021 Aug; 5(16):3134-3146. PubMed ID: 34424317 [TBL] [Abstract][Full Text] [Related]
18. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Yi X; Jain N; Iles LR; Ayres ML; Wierda WG; Gandhi V Front Oncol; 2022; 12():833714. PubMed ID: 35273915 [TBL] [Abstract][Full Text] [Related]
19. Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia. Montoya S; Thompson MC Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509309 [TBL] [Abstract][Full Text] [Related]
20. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]